reports
EQS-News: MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Stud...
EQS-News: MorphoSys AG / Schlagwort(e): Konferenz MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 24.04.2024 / 16:40 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Planegg/München, Deutschland, 24. April 2024 MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 Weitere Posterpräsentation im Rahmen von ASCO 2024 zeigt neue Er...
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabres...
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat Morpho...
Schweiter Technologies Ag: 1 director
A director at Schweiter Technologies Ag bought 150 shares at 412.748CHF and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
Invitation til præsentation af ALK’s regnskab for første kvartal freda...
Invitation til præsentation af ALK’s regnskab for første kvartal fredag den 3. maj 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første tre måneder af 2024 (Q1) om morgenen fredag den 3. maj 2024. ALK afholder senere samme dag kl. 12.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR chef. Live audio webcast Mødet audiocastes live på , hvor genafspiln...
Invitation to the presentation of ALK’s first quarter results on Frida...
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET, where ALK’s management will comment on the first quarter results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be availabl...
Xtract One Closes $7.2M Public Offering and $1.4M Investment by Strate...
Xtract One Closes $7.2M Public Offering and $1.4M Investment by Strategic Partner THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) announces that it has closed its previously announced public offering (the “Offering”) conducted by Eight Capital, as lead agent and sole bookrunner, and Echelon Wealth Partners Inc. (together wit...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary F...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transforma...
EQS-News: Cherry SE: Neubewertung von Vermögensgegenständen
EQS-News: Cherry SE / Schlagwort(e): Sonstiges Cherry SE: Neubewertung von Vermögensgegenständen 24.04.2024 / 16:23 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. München, 24. April 2024 – Cherry SE korrigiert alte Annahmen zur Unternehmensentwicklung und nimmt konservative, nicht zahlungswirksame Neubewertungen vor Die Cherry SE nimmt bilanzielle Wertberichtigungen von Vermögensgegenständen im Jahresabschluss 2023 vor. Diese nicht-zahlungswirksamen Abschreibungen betreffen immaterielle Vermögenswerte, im Wesentlichen den Goodwill, ...
EQS-News: Cherry SE: Revaluation of assets
EQS-News: Cherry SE / Key word(s): Miscellaneous Cherry SE: Revaluation of assets 24.04.2024 / 16:23 CET/CEST The issuer is solely responsible for the content of this announcement. Munich, 24. April 2024 - Cherry SE corrects old assumptions about the company's development and carries out conservative, non cash-effective revaluations Cherry SE is recognizing asst impairments in the 2023 annual financial statements. These non-cash items relate to intangible assets, mainly goodwill, as well as property, plant and equipment and amount to approximately EUR 96 million. Accordi...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of CITGO Holding, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 April 2024 in which Moody's reassessed the appropriateness of the ratings in the con...
Ensari Deri Gida Sanayi Ve Ticaret A S: 1 director
A director at Ensari Deri Gida Sanayi Ve Ticaret A S sold 4,425,000 shares at 25.340TRY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
Fly Play hf.: Increase of share capital
Fly Play hf.: Increase of share capital Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a meeting today to increase the Company's share capital by issuing 1...
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...
T-Mobile Unveils BIG Moves to Help Small Businesses Grow
BELLEVUE, Wash.--(BUSINESS WIRE)-- It’s nearly Small Business Week and T-Mobile is going big for small business customers with deals starting April 25! T-Mobile is launching Business Unlimited Edge and new small business customers that add at least 10 or more lines can get up to a $1,000 credit for each voice line on Business Unlimited Edge – that’s like $10,000 back in their pockets! And that’s just the beginning. With T-Mobile, businesses can score a year of Amazon Business Prime Essentials plan membership on Us (a $179 value!)! Customers can also enjoy TONS of great resources that help sm...
Sýn hf.: Breyting á Fjárhagsdagatali 2024
Sýn hf.: Breyting á Fjárhagsdagatali 2024 Sýn hf. tilkynnir hér með um breytingu á fjárhagsdagatali sem birt var þann 25. janúar 2024. Breytingin lýtur að afkomubirtingu vegna árshlutareiknings 1F 2024, sem færist fram um einn dag og verður 7. maí í stað 8. maí. Fjárfestakynningar munu fara fram í tengslum við birtingu á afkomu 2F og afkomu 4F (ársuppgjörs). Afkoma 4F og ársuppgjör 202327. febrúar 2024Aðalfundur11. apríl 2024Afkoma 1F 20247. maí 2024Afkoma 2F 202428. ágúst 2024Afkoma 3F 20246. nóvember 2024Afkoma 4F og ársuppgjör 202419. febrúar 2025Aðalfundur14. mars 2025 Vinsamlegast athu...
Hilton Grand Vacations Unveils 2024 Brand Ambassadors to Headline Excl...
ORLANDO, Fla.--(BUSINESS WIRE)-- (NYSE:HGV), the premier vacation ownership and experiences company, announces its 2024 Hilton Grand Vacation Brand Ambassadors, including legendary golfer Annika Sörenstam, iconic musician Joey Fatone, singer and actress Katharine McPhee and others. These brand ambassadors will be a central part of the thousands of exclusive private events hosted for HGV members throughout the year, including concerts, sporting events and private chef dinners. HGV is at the forefront of experiential travel, leading the industry in unique offerings and meeting the growing dem...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Eval...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicag...
EQS-News: FCR Immobilien AG: Fristgerechte Rückzahlung 5,25 %-Anleihe ...
EQS-News: FCR Immobilien AG / Schlagwort(e): Anleihe FCR Immobilien AG: Fristgerechte Rückzahlung 5,25 %-Anleihe 2019/2024 24.04.2024 / 16:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. FCR Immobilien AG: Fristgerechte Rückzahlung 5,25 %-Anleihe 2019/2024 Pullach im Isartal, 24.04.2024: Die FCR Immobilien AG (“FCR”, ISIN DE000A1YC913) hat mit heutigem Tag den Gesamtbetrag der 5,25 %-Anleihe (WKN: A2TSB1) an das Bankhaus Gebr. Martin AG, vorzeitig überwiesen. Die Ausschüttung erfolgt ab 30.04.2024 seitens der Clearstream Banking...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.